Posterior Juxtascleral Depot Administration of Anecortave Acetate

Survey of Ophthalmology

Volumn 52, Issue 1 SUPPL., 2007, Pages

  Kaiser, Peter K ^a   Goldberg, Morton F ^b   Davis, Alberta A ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

AMD; anecortave acetate; posterior juxtascleral depot (PJD)

Indexed keywords

ANECORTAVE;

ABSENCE OF SIDE EFFECTS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANNULA; CHOROID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; ENDOPHTHALMITIS; HUMAN; MONKEY; NONHUMAN; POSTERIOR JUXTASCLERAL DEPOT DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RETINA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CATHETERIZATION; CHOROIDAL NEOVASCULARIZATION; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; PREGNADIENEDIOLS; SCLERA;

EID: 33846220906     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2006.10.015     Document Type: Article

References (15)

1. BenEzra D., Griffin B.W., Maftzir G., et al. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 38 (1997) 1954-1962
2. Bressler N.M., Bressler S.B., West S.K., et al. The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol 107 (1989) 847-852
3. Clark A.F. AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin Investig Drugs 6 (1997) 1867-1877
4. Clark A.F., Mellon J., Li X.Y., et al. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci 40 (1999) 2158-2162
5. Dahlin D., and Rahimy M.H. Pharmacokinetics and metabolism of anecortave acetate in animals and humans. Surv Ophthalmol 52 Suppl 1 (2007) S49-S61
6. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 110 (2003) 2372-2383 discussion 2384-5
7. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 23 (2003) 14-23
8. Kahn H.A., Leibowitz H.M., Ganley J.P., et al. The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol 106 (1977) 33-41
9. Klein R., Klein B.E., and Linton K.L. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99 (1992) 933-943
10. Leibowitz HM, Krueger DE, Maunder LR, et al: Framingham Eye Study Surv Ophthalmol 24(Suppl):335-610, 1980
11. McNatt L.G., Weimer L., Yanni J., et al. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther 15 (1999) 413-423
12. Mitchell P., Smith W., Attebo K., et al. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 102 (1995) 1450-1460
13. Penn J.S., Rajaratnam V.S., Collier R.J., et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 42 (2001) 283-290
14. Regillo C.D., D'Amico D.J., and Mieler W.F. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with PDT. Surv Ophthalmol 52 Suppl 1 (2007) S70-S78
15. van Leeuwen R., Klaver C.C., Vingerling J.R., et al. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol 121 (2003) 519-526